IO Biotech concludes subject enrollment in melanoma vaccine trial

IO Biotech has concluded subject enrolment in the Phase III IOB-013/KN-D18 clinical trial for IO102-IO103 combination therapy to treat advanced melanoma.

Sponsored by IO Biotech, the randomised, open-label pivotal trial will analyse IO102-IO103 along with pembrolizumab compared to pembrolizumab alone for priorly untreated, unresectable or metastatic (advanced) melanoma.